Skip to content

LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability

The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology platform.

The LIDDS presentation goes live at 10.20 and can be followed on the following link:
The video can also be viewed later at or

For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22,

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). For more information, please visit

The News in PDF

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire